PP405 is a topical gel being tested for hair regrowth in adults with androgenetic alopecia. Volunteers aged 18-55 are needed for a 16-week trial in several US locations.
The conclusion of the conversation is that the user has made significant progress in their hair loss treatment using a combination of oral minoxidil, topical minoxidil, RU58841, dutasteride, dermarolling, and scalp massage. Other users have praised their progress and recommended different treatments.
The user was rejected from participating in a clinical trial for an extended-release oral Minoxidil due to having rheumatoid arthritis, despite initially being accepted. They had stopped using Dutasteride and Minoxidil to qualify but continued using other treatments like RU58841 and red light therapy.
The conversation is about finding an affordable and effective low level laser therapy device for hair loss, with a preference for a cap but open to a comb.
The post and conversation are about a user's 6-month hair loss progress using 0.5 mg dutasteride daily and 2.5 mg oral minoxidil daily. Users congratulate the progress and discuss the effectiveness of the treatment.
The conversation is about someone wanting to import RU58841 or CB-03-01 from China for hair loss treatment but being concerned about receiving counterfeit products. Specific treatments mentioned are RU58841 and CB-03-01.
The user has androgenetic alopecia (AGA) and low Vitamin D levels, and they started using topical minoxidil (5%). They are considering finasteride but are concerned about side effects and are advised to seek mental health support.
A user from China is participating in a clinical trial for Pyrilutamid, a potential hair loss treatment originally developed for prostate cancer. They've experienced no side effects except initial scalp itchiness, and will share results after the year-long trial.
User's 2-month hair loss treatment includes Dut 0.5mg, oral min 2.5mg, Dut+PRP mesotherapy, microneedling, and other products. Dermatologist increased min dose to 5mg, expecting better results at 6-month mark.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
A user shared their 9-month post-hair transplant results with 4600 grafts, using only Nourkin hair vitamins, Vitamin D, and B12, and expressed satisfaction. The replies debated the necessity of medications like finasteride and minoxidil for maintaining hair health.
The user is using 5% minoxidil, 1mg finasteride, and a 1.5mm dermaroller 1-2 times a week for hair growth, noting improved growth speed and density. They avoid applying minoxidil immediately after dermarolling due to skin irritation.
The conversation discusses a new product from Actifolic, which combines RU58841 and GHK-CU for hair loss treatment. The participants are considering whether it's worth trying.
The user has been using minoxidil for a year, finasteride for 7 weeks, and incorporates derma rolling and rosemary oil into their routine, resulting in noticeable hair growth and thickness. They report minimal side effects and are considering sharing more progress photos due to positive feedback.
A 29-year-old is using 1mg oral finasteride and 50mg/g topical minoxidil daily for hair loss, with plans to reduce minoxidil use due to greasiness and considering a hair transplant for receding temples. No side effects from finasteride were reported, and many users suggest a transplant may not be necessary due to good hair density.
The user shared their successful hair regrowth journey using a combination of oral Dutasteride and a topical mix of Finasteride, Minoxidil, Tretinoin, and Ketoconazole. They experienced no side effects and noted significant improvement, except for one persistent thinning area.
After a year on dutasteride and oral minoxidil, the user experienced significant hair regrowth, improving from Norwood 2 to almost Norwood 1. They added RU58841, microneedling, rosemary oil, GHK-Cu, and annurca apple supplement to their regimen and are now noticing hair loss in the temple area.
A 36-year-old had a hair transplant with 6,500 grafts 7 months ago, took 1.25mg of finasteride every other day for 5 months, and recently switched to 1mg daily along with 5% minoxidil spray. They are considering a touch-up transplant and are seeking advice on their progress and future expectations.
The user has been using finasteride, minoxidil, a dermastamp, and red light therapy for six months with no visible improvement since the three-month mark. Other users noted improvement, particularly in the left temple area, and encouraged the user to continue.
The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
User started with rosemary oil, then used oral minoxidil, topical minoxidil, dutasteride, RU58841, derma rolling, and keto for hair loss treatment. Significant progress was made, and others praised the aggressive approach.
A user shared their 20-week progress using topical minoxidil (5%) and finasteride (0.1%) with a 1mm dermastamp, showing significant hair regrowth from NW5 to between NW3V and NW4. They experienced no side effects and plan to update at 12 months.
A user is using topical finasteride, keto shampoo, microneedling, and tretinoin for hair loss and is considering adding pyrilutamide. They notice some improvement at the temples and seek advice on whether to focus on cosmetic results despite daily shedding.
PP405 is a potential hair loss treatment that inhibits mitochondrial pyruvate carriers, increasing lactate dehydrogenase activity and stimulating hair follicle stem cells. In a phase 1 trial, 31% of participants showed over 20% hair density increase with PP405 treatment.
A female user's experience using Spironolactone to treat Female Pattern Hair Loss (FPHL) and Androgenic Alopecia, as well as discussing the effectiveness of the drug at different dosages.
The conversation discusses hair loss and treatments, with users suggesting the original poster's hair has receded despite using a dermaroller and RU58841 for two months. Many recommend starting finasteride and minoxidil for better results.
A 26-year-old individual treating hair loss since 19, using a regimen of Finasteride, Cyproterone, Oral Minoxidil, Microneedling, Dutasteride, and newly added RU58841. They're seeking advice from other RU58841 users about their experiences.
Fluridil is hard to obtain and only available in Slovakia and Czechia, with no systemic side effects but possibly limited effectiveness compared to finasteride. The original poster is using finasteride and minoxidil without success and is considering trying fluridil despite its cost.